Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 312

Results For "SSI"

5643 News Found

Lonza launches new cell culture media system TheraPRO
News | July 18, 2023

Lonza launches new cell culture media system TheraPRO

The two-part production system is proven to yield high-quality proteins from GS-CHO cell lines, a prevalent mammalian host cell for protein production


PredOmix, Core Diagnostics partner to launch OncoVeryx-F
Clinical Trials | July 18, 2023

PredOmix, Core Diagnostics partner to launch OncoVeryx-F

OncoVeryx-F, a proprietary test developed by PredOmix, is set to transform early-stage cancer detection


CARER collaborates with Wholeleaf to enhance holistic cancer care services
News | July 17, 2023

CARER collaborates with Wholeleaf to enhance holistic cancer care services

The collaboration between CARER and Wholeleaf aims to offer an integrated approach to cancer patients, combining services and products to optimize their well-being


Singapore hosts start-up immersion programme for Indian MBBS doctors
News | July 11, 2023

Singapore hosts start-up immersion programme for Indian MBBS doctors

The programme was conducted as a part of MPMCx, an exclusive management programme for MBBS doctors by IIM-Ahmedabad in collaboration with DailyRounds


Bausch + Lomb acquires Blink eye drops
Healthcare | July 11, 2023

Bausch + Lomb acquires Blink eye drops

The strategic acquisition demonstrates the company’s commitment to increasing OTC consumer convenience in eye care


NMPA approval for first BCMA CAR-T Therapy paves way for more multiple myeloma cell therapies, says GlobalData
Drug Approval | July 11, 2023

NMPA approval for first BCMA CAR-T Therapy paves way for more multiple myeloma cell therapies, says GlobalData

Approval to dramatically change CAR-T therapies landscape


Sumitomo Pharma America launches as new combined organization
News | July 11, 2023

Sumitomo Pharma America launches as new combined organization

SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets